CTLA4 and neoplasm: And ILC3 depletion obviously impaired the effectiveness of anti-PD-1 and anti-CTLA-4 therapy in CRC, indicating that ILC3 operates as an essential protective agent for ICB immunotherapy to exert effective anti-tumor effects (126, 163).